Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.3950
-0.0048 (-1.20%)
At close: Oct 2, 2026, 4:00 PM EDT
0.3952
+0.0002 (0.05%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Ensysce Biosciences Employees
As of December 31, 2025, Ensysce Biosciences had 10 total employees, including 8 full-time and 2 part-time employees. The number of employees increased by 2 or 25.00% compared to the previous year.
Employees
10
Change (1Y)
2
Growth (1Y)
25.00%
Revenue / Employee
$450,075
Profits / Employee
-$1,262,390
Market Cap
7.69M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | 2 | 25.00% | 8 | 2 |
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 6 | 0 |
| Sep 30, 2021 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 4 | - | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| Enlivex | 34 |
| Imunon | 20 |
| NeuroSense Therapeutics | 17 |
| Soligenix | 14 |
| Azitra | 13 |
| CNS Pharmaceuticals | 8 |
| KALA BIO | 6 |
ENSC News
- 9 days ago - Ensysce Biosciences submits Phase 2 protocol for CY200 to UK MHRA - TheFly
- 9 days ago - Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA - Accesswire
- 18 days ago - Ensysce Biosciences advances CRPS program at Painweek 2026 - TheFly
- 18 days ago - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation - Accesswire
- 19 days ago - Ensysce professor to speak at FDA public hearing on psychedelic drugs - TheFly
- 19 days ago - Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Accesswire
- 4 weeks ago - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation - Accesswire
- 4 weeks ago - Ensysce completes enrollment for final phase of PF614-MPAR-102 study - TheFly